コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 y for safely and noninvasively treating this debilitating disease.
2 ver spontaneously, but some develop chronic, debilitating disease.
3 e bedsides of patients with this chronic and debilitating disease.
4 thritis has reinvigorated research into this debilitating disease.
5 novel therapeutic targets for, this chronic, debilitating disease.
6 or treat the vascular complications of this debilitating disease.
7 apeutic strategies for the treatment of this debilitating disease.
8 risk because of old age (> 70 yr) or serious debilitating disease.
9 n of specific prevention strategies for this debilitating disease.
10 ncover novel therapeutic strategies for this debilitating disease.
11 approaches to the management of this common, debilitating disease.
12 or the discovery of novel therapies for this debilitating disease.
13 ating new and existing therapeutics for this debilitating disease.
14 es of progression to higher severity of this debilitating disease.
15 possible personalized medicine for this very debilitating disease.
16 ation of myosin motors, as mutations lead to debilitating disease.
17 autoimmune axis in the pathogenesis of this debilitating disease.
18 n human diseased tissue that facilitate this debilitating disease.
19 and a potential therapeutic target for this debilitating disease.
20 of Na(V)1.7 and lead to severe pain in this debilitating disease.
21 and effective therapeutic strategy for this debilitating disease.
22 ential new therapeutic avenues to treat this debilitating disease.
23 ess challenges in unresponsive cases of this debilitating disease.
24 advances in understanding and treating this debilitating disease.
25 nd treatment of patients suffering from this debilitating disease.
26 , and millions have suffered from the highly debilitating disease.
27 eatment, and follow-up in patients with this debilitating disease.
28 ) provides a potential gene therapy for this debilitating disease.
29 n, which causes periodic outbreaks of highly debilitating disease.
30 e tested now to slow the progression of this debilitating disease.
31 apies currently under investigation for this debilitating disease.
32 s suggest novel therapeutic targets for this debilitating disease.
33 at increasing frataxin levels to treat this debilitating disease.
34 ggests alternative treatments for this often-debilitating disease.
35 strategies that are aimed at preventing this debilitating disease.
36 n resistance that are characteristic of this debilitating disease.
37 low Quarter Horse breeders to eliminate this debilitating disease.
38 d there are currently no treatments for this debilitating disease.
39 those afflicted by this rare and potentially debilitating disease.
40 based on soluble pathogenic markers for the debilitating disease.
41 ng, measuring, and ultimately treating these debilitating diseases.
42 nt continued occurrence of these potentially debilitating diseases.
43 patients with cognitive decline due to other debilitating diseases.
44 , and dysregulation of UPR underlies several debilitating diseases.
45 ochondrial Ca(2+) handling can contribute to debilitating diseases.
46 act on treatment of SHP-2 dysfunction linked debilitating diseases.
47 approach for treating otherwise terminal or debilitating diseases.
48 are being developed to ameliorate otherwise debilitating diseases.
49 ADAM17 is implicated in several debilitating diseases.
50 ens which cause periodic outbreaks of highly debilitating diseases.
51 alliative treatments exist for this group of debilitating diseases.
52 peutic strategies for the treatment of these debilitating diseases.
53 ide is a contributing factor of many chronic debilitating diseases.
54 atic, some progress to develop the fatal and debilitating disease adult T-cell leukemia/lymphoma (ATL
58 ain.SIGNIFICANCE STATEMENT Chronic pain is a debilitating disease affecting approximately one in thre
64 ntravascular, parasitic flatworms that cause debilitating disease afflicting >200 million people.
65 hematopoietic response to schistosomiasis, a debilitating disease afflicting more than 200 million pe
66 asitic helminths that cause a chronic, often debilitating disease afflicting over 200 million people
68 Understanding the mechanisms that cause this debilitating disease and identifying biomarkers for diag
70 (WHO) set ambitious goals of control of this debilitating disease and its elimination as a public hea
72 ogical levels, trigger the onset of multiple debilitating diseases and lead to a loss of function, an
73 We discuss selected mycoviruses that cause debilitating diseases and/or reduce the virulence of the
74 ebrate hosts, in which EEEV induces a highly debilitating disease, and the outcomes are frequently le
75 Dysregulation of human NSTs causes several debilitating diseases, and NSTs are virulence factors fo
76 formed the therapeutic landscape for several debilitating diseases, and the clinical outlook for gene
77 yloid aggregates are associated with several debilitating diseases, and there are numerous efforts to
79 athic pulmonary fibrosis (IPF) is a severely debilitating disease associated with a dismal prognosis.
80 th nasal polyps (CRSwNP) can be a severe and debilitating disease associated with significant morbidi
81 eutic strategies for the treatment of severe debilitating diseases associated with type I IFNs due to
83 derived from clone p19/wenv17 caused severe debilitating disease at 5 to 7 days postinfection; initi
85 atients with GNE myopathy, a progressive and debilitating disease caused by a genetic defect in siali
86 ic obstructive pulmonary disease (COPD) is a debilitating disease caused by chronic exposure to cigar
88 loidosis is an underdiagnosed, progressively debilitating disease caused by mutations in the transthy
91 ular necrosis of the femur head (AVNFH) is a debilitating disease caused due to the use of alcohol, s
93 erited restrictive cardiomyopathy (RCM) is a debilitating disease characterized by a stiff heart with
95 egypti and Ae. albopictus mosquitoes, causes debilitating disease characterized by an acute febrile p
96 stomatitis (FCGS) is a relatively common and debilitating disease characterized by bilateral inflamma
98 e systemic sclerosis (SSc; scleroderma) is a debilitating disease characterized by excessive dermal f
104 wel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory
105 s into amyloid fibrils is a hallmark of many debilitating diseases, from Alzheimer's and Parkinson di
106 fected; knowledge critical for understanding debilitating disease hallmarks, including cardiovascular
109 Protein aggregation is associated with many debilitating diseases including Alzheimer's, Parkinson's
111 y and resolution, hindering the diagnosis of debilitating diseases including phenylketonuria, tyrosin
114 human use, the possibility of CHIKV-induced debilitating disease is high in many parts of the world.
116 ic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life limi
117 lostridioides difficile infection (CDI) is a debilitating disease leading to poor health-related qual
118 cted to molecular alterations giving rise to debilitating diseases like rheumatoid arthritis and oste
119 Septic arthritis is a severe and rapidly debilitating disease mainly caused by Staphylococcus aur
122 Osteoarthritis (OA) is a common, painful and debilitating disease of articulating joints resulting fr
131 rebellar ataxias are a group of progressive, debilitating diseases often associated with abnormal Pur
132 al Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions document was issued
137 ve multifocal leukoencephalopathy (PML) is a debilitating disease resulting from infection of oligode
140 r bacteria that cause brucellosis, a chronic debilitating disease significantly impacting global heal
142 ng pathogens and pollution, that can lead to debilitating diseases such as asthma and chronic obstruc
143 lasticity could result in the development of debilitating diseases such as cancer, fibrosis, atherosc
144 to provide cell replacement therapy to treat debilitating diseases such as diabetes, Parkinson's and
145 he gastrointestinal (GI) tract that includes debilitating diseases, such as ulcerative colitis (UC) a
146 tus is the causative agent of brucellosis, a debilitating disease that affects humans and animals.
147 is responsible for Chagas disease, a serious debilitating disease that affects millions of people in
148 a high-risk locus for multiple sclerosis, a debilitating disease that also presents with excess iron
149 candidates.IMPORTANCE Chikungunya fever is a debilitating disease that causes severe pain to the join
152 rculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centu
153 e pulmonary disease (COPD) is a progressive, debilitating disease that in its final stages cripples t
155 chronic lymphatic insufficiency-is a chronic debilitating disease that is frequently misdiagnosed, tr
160 n the subject of intense research due to the debilitating diseases that result from its dysfunction.
162 (5-FU) is the first line of therapy for this debilitating disease, treatment effectiveness is often h
163 the gut flora of children affected with this debilitating disease using shotgun metagenomic sequencin
164 Posttraumatic stress disorder (PTSD) is a debilitating disease, which affects 8-10% of the populat
165 scular necrosis of femoral head (AVNFH) is a debilitating disease, which affects the middle aged popu
166 tissues leads to a multisystemic and highly debilitating disease whose main features are dark urine,
170 -Gilford progeria syndrome (HGPS) is a rare, debilitating disease with early mortality and rapid onse
172 hronic fatigue syndrome (ME/CFS) is a highly debilitating disease with heterogeneous constitutional a
177 s/chronic fatigue syndrome (ME) is a severe, debilitating disease, with substantial evidence pointing
178 oping more effective therapies against these debilitating diseases, with the potential for broader ap